Upstream Bio, a clinical-stage biopharmaceutical company focused on inflammatory disease treatments, plans to unveil key findings from its Phase 2 clinical trial of verekitug. The announcement is scheduled for Tuesday, September 2nd.
The Phase 2 VIBRANT trial (NCT06164704) evaluated the efficacy and safety profile of verekitug in patients diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial involved a global, randomized, placebo-controlled design, comparing verekitug to a placebo.
Participants received either 100 mg of verekitug or a placebo subcutaneously every twelve weeks over a 24-week period. The primary endpoint measured the change in endoscopic nasal polyp score (NPS) at the 24-week mark.
Upstream Bio will host a conference call and webcast to discuss the results on September 2nd at 8:00 a.m. ET. The company will provide a detailed analysis of the data during this event. A recording of the webcast will be archived on the company’s investor relations website for those unable to attend live.
Verekitug is a monoclonal antibody that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine identified as a key driver in inflammatory responses. Upstream Bio is currently investigating verekitug in several Phase 2 trials targeting various inflammatory respiratory diseases.
The company believes verekitug holds significant potential for patients with unmet needs in the treatment of severe respiratory disorders. The results of the VIBRANT trial are highly anticipated within the medical community. Further details regarding the trial’s findings will be released following the September 2nd conference call. Upstream Bio is committed to advancing its pipeline to address these significant unmet medical needs.
Related
